Biopharma dealmaking: predictions for 2024
European Pharmaceutical Review
DECEMBER 30, 2023
The past 12 months has seen significant growth in global mergers and acquisitions (M&A) within the biopharma sector. This activity is expected to continue in 2024, with increasing need for biopharma to access innovation through collaboration and dealmaking to offset looming patent challenges. “In 2023, total life sciences deal value increased by 34 percent to $191 billion.
Let's personalize your content